within Pharmacolibrary.Drugs.C_CardiovascularSystem.C09C_AngiotensinIiReceptorBlockersArbsPlain.C09CA09_AzilsartanMedoxomil;

model AzilsartanMedoxomil
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.6,
    Cl = 6.388888888888888e-07,
    adminDuration = 600,
    adminMass = 80 / 1000000,
    adminCount = 1,
    Vd = 0.0161,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.018333333333333333,
    Tlag = 10.200000000000001,
    Vdp = 0.0076,
    k12 = 1.2777777777777777e-06,
    k21 = 1.2777777777777777e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>AzilsartanMedoxomil</td></tr><tr><td>ATC code:</td><td>C09CA09</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>80</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>16.1</td><td>L</td></tr>
    <tr><td>clearance:</td><td>2.3</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Azilsartan medoxomil is an angiotensin II receptor blocker (ARB) used primarily for the treatment of hypertension. It is an orally administered prodrug that is hydrolyzed to the active metabolite azilsartan. Azilsartan medoxomil is approved and marketed in several countries including the US and EU for blood pressure control.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult male and female subjects after a single oral dose.</p><h4>References</h4><ol><li><p>Tsai, MC, et al., &amp; Vakilynejad, M (2016). Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With Stage 2 Hypertension. <i>Journal of clinical pharmacology</i> 56(8) 988–998. DOI:<a href=\"https://doi.org/10.1002/jcph.684\">10.1002/jcph.684</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26632101/\">https://pubmed.ncbi.nlm.nih.gov/26632101</a></p></li><li><p>Harrell, RE, et al., &amp; Dudkowski, C (2016). Effects of Age, Sex, and Race on the Safety and Pharmacokinetics of Single and Multiple Doses of Azilsartan Medoxomil in Healthy Subjects. <i>Clinical pharmacokinetics</i> 55(5) 595–604. DOI:<a href=\"https://doi.org/10.1007/s40262-015-0333-8\">10.1007/s40262-015-0333-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26507722/\">https://pubmed.ncbi.nlm.nih.gov/26507722</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C09CA09 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end AzilsartanMedoxomil;
